Carlyle’s ₹1,750 crore Piramal Pharma 6% block deal likely called off; shares fall 3%
AI Market Summary
Carlyle's planned 6% Piramal Pharma block sale was reportedly cancelled due to tepid investor demand, pressuring the stock (~-3%) despite strong Q1 revenue and EBITDA growth. The cancellation signals weaker near-term appetite for secondary placements in Indian equities and may weigh on sentiment toward similar sponsor-led stake sales, though broader market impact should remain limited.
Impact level
● Low
Affected assets
NCSINIFTY52USD/USDT+0.05%
AI Insight · NCSINIFTY52USD/USDTAI Insight
▼ Bearish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Private equity firm Carlyle was set to sell a 6% stake in Piramal Pharma via a ₹1,750 crore block deal, but the transaction is likely to have been cancelled. The stock fell about 3% after the update. As of the end of the June quarter, promoter entities held 34.8% while public shareholding stood at 64.72%. Piramal Pharma reported first-quarter revenue up 17.4% to ₹2,269.9 crore and EBITDA up 82.9% to ₹195.2 crore, lifting margin to 8.6% from 5.5%.
